Wen-Juei Jeng (Markus Cornberg)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 56

Top Topics

Hepatitis B Virus

Prognostic Factors

Helicobacter Pylori

Top Venues

Alimentary pharmacology & therapeutics

Hepatology (Baltimore, Md.)

Hepatology communications

Liver international : official journal of the International Association for the Study of the Liver

This page only lists publications with an associated author ORCID identifier.

Publications

Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
Editorial: High qHBsAg-Is it a good or bad signal? Authors' reply. Alimentary pharmacology & therapeutics 59 (12) (2024)
Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
Editorial: High qHBsAg-Is it a good or bad signal? Authors' reply. Alimentary pharmacology & therapeutics 59 (12) (2024)
Hsin-Che Lin, Wen-Juei Jeng, Jessica Liu, Mei-Hung Pan, Mei-Hsuan Lee, Richard Batrla-Utermann, Sheng-Nan Lu, Chuen-Fei Chen, Hwai-I Yang, Chien-Jen Chen
Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. Alimentary pharmacology & therapeutics 59 (8) (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics (2024)
Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, Tung-Hung Su, Grace Lai-Hung Wong, Wai Kay Seto, Arno Furquim d'Almeida, Margarita Papatheodoridi, Sylvia M Brakenhoff, Sabela Lens, Hannah S J Choi, Rong-Nan Chien, Jordan J Feld, Xavier Forns, Milan J Sonneveld, Georgios Papatheodoridis, Thomas Vanwolleghem, Man Fung Yuen, Henry Lik Yuen Chan, Jia-Horng Kao, Yao-Chun Hsu, Markus Cornberg, Wen-Juei Jeng, Harry L A Janssen, null null
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). The American journal of gastroenterology (2024)
Hsin-Che Lin, Wen-Juei Jeng, Jessica Liu, Mei-Hung Pan, Mei-Hsuan Lee, Richard Batrla-Utermann, Sheng-Nan Lu, Chuen-Fei Chen, Hwai-I Yang, Chien-Jen Chen
Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. Alimentary pharmacology & therapeutics 59 (8) (2024)
Hsin-Che Lin, Wen-Juei Jeng, Jessica Liu, Mei-Hung Pan, Mei-Hsuan Lee, Richard Batrla-Utermann, Sheng-Nan Lu, Chuen-Fei Chen, Hwai-I Yang, Chien-Jen Chen
Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. Alimentary pharmacology & therapeutics (2024)
Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
Letter: Association of persistently high HBsAg levels during HBeAg-seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients-Authors' reply. Alimentary pharmacology & therapeutics 59 (11) (2024)
Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
Letter: Association of persistently high HBsAg levels during HBeAg-seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients-Authors' reply. Alimentary pharmacology & therapeutics 59 (11) (2024)
Hsin-Che Lin, Wen-Juei Jeng, Jessica Liu, Mei-Hung Pan, Mei-Hsuan Lee, Richard Batrla-Utermann, Sheng-Nan Lu, Chuen-Fei Chen, Hwai-I Yang, Chien-Jen Chen
Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. Alimentary pharmacology & therapeutics 59 (8) (2024)
Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Reply: New confounders emerging with new evidence regarding reduced HCC and improved survival. Hepatology (Baltimore, Md.) (2024)
Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, Tung-Hung Su, Grace Lai-Hung Wong, Wai Kay Seto, Arno Furquim d'Almeida, Margarita Papatheodoridi, Sylvia M Brakenhoff, Sabela Lens, Hannah S J Choi, Rong-Nan Chien, Jordan J Feld, Xavier Forns, Milan J Sonneveld, Georgios Papatheodoridis, Thomas Vanwolleghem, Man Fung Yuen, Henry Lik Yuen Chan, Jia-Horng Kao, Yao-Chun Hsu, Markus Cornberg, Wen-Juei Jeng, Harry L A Janssen, null null
Limited sustained remission after nucleos(t)ide analogue withdrawal: Results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study). The American journal of gastroenterology (2024)
Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
Letter: Association of persistently high HBsAg levels during HBeAg-seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients-Authors' reply. Alimentary pharmacology & therapeutics (2024)
Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
Editorial: High qHBsAg-Is it a good or bad signal? Authors' reply. Alimentary pharmacology & therapeutics (2024)
Hsin-Che Lin, Wen-Juei Jeng, Jessica Liu, Mei-Hung Pan, Mei-Hsuan Lee, Richard Batrla-Utermann, Sheng-Nan Lu, Chuen-Fei Chen, Hwai-I Yang, Chien-Jen Chen
Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. Alimentary pharmacology & therapeutics 59 (8) (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
Editorial: High qHBsAg-Is it a good or bad signal? Authors' reply. Alimentary pharmacology & therapeutics 59 (12) (2024)
Yen-Chun Liu, Wen-Juei Jeng
Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients. Alimentary pharmacology & therapeutics 57 (5) (2023)
Wen-Juei Jeng, Anna S F Lok
What will it take to cure hepatitis B? Hepatology communications 7 (4) (2023)
Wen-Juei Jeng, Anna S F Lok
What will it take to cure hepatitis B? Hepatology communications 7 (4) (2023)
Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game? Hepatology (Baltimore, Md.) 79 (5) (2023)
Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game? Hepatology (Baltimore, Md.) (2023)
Yen-Chun Liu, Wen-Juei Jeng, Rong-Nan Chien
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection. Alimentary pharmacology & therapeutics 58 (7) (2023)
Wen-Juei Jeng, Anna S F Lok
What will it take to cure hepatitis B? Hepatology communications 7 (4) (2023)
Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game? Hepatology (Baltimore, Md.) 79 (5) (2023)
Hui-Han Hu, Wen-Juei Jeng, Mei-Hung Pan, Wun-Sheng Luo, Chia-Ling Chang, Yen-Tsung Huang, Chien-Yu Su, Chen-Tse Chiang, Chin-Lan Jen, Yu-Chuan Chien, Sheng-Nan Lu, Li-Yu Wang, Li-Rung Huang, Mei-Hsuan Lee, Jessica Liu, Mindie H Nguyen, Chien-Jen Chen, Hwai-I Yang
Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B. Alimentary pharmacology & therapeutics 55 (5) (2022)
Yen-Chun Liu, Wen-Juei Jeng
Letter: the probability of predicting HBV-specific CD8+ cell response derived from HLA-A2+ may not closely predict functional cure in Asian patients who stop nucleoside analogues. Alimentary pharmacology & therapeutics 56 (8) (2022)
Wen-Juei Jeng, Chien-Hung Chen, Yi-Wen Wang, Mei-Hung Pan, Chia-Wei Lin, Chun-Yen Lin, Hwai-I Yang
The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays. Virology journal 19 (1) (2022)
Yun-Fan Liaw, Wen-Juei Jeng, Rong-Nan Chien
Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy. Liver international : official journal of the International Association for the Study of the Liver 42 (4) (2022)
Yen-Chun Liu, Ya-Ting Cheng, Yi-Cheng Chen, Yi-Chung Hsieh, Wen-Juei Jeng, Chun-Yen Lin, Rong-Nan Chien, Dar-In Tai, I-Shyan Sheen
Correction: Comparing Predictability of Non‑invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients. Digestive diseases and sciences (2022)
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, Wei-Ting Chen, Yi-Chung Hsieh, Chien-Hao Huang, Kar-Wai Lui, Chen-Fu Hung, Ching-Ting Wang, Pei-Mei Chai, Chen-Chun Lin, Yung-Chang Lin, Shi-Ming Lin, I-Shyan Sheen
Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. Diagnostics (Basel, Switzerland) 12 (3) (2022)
Chung-Wei Su, Wei Teng, Po-Ting Lin, Wen-Juei Jeng, Kuei-An Chen, Jason Chia-Hsun Hsieh, Wei-Ting Chen, Ming-Mo Ho, Chia-Hsun Hsieh, Ching-Ting Wang, Pei-Mei Chai, Chen-Chun Lin, Yung-Chang Lin, Shi-Ming Lin
Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer medicine (2022)
Chien-Hao Huang, Jian-He Fan, Wen-Juei Jeng, Shu-Ting Chang, Chan-Keng Yang, Wei Teng, Tsung-Han Wu, Yi-Chung Hsieh, Wei-Ting Chen, Yi-Cheng Chen, I-Shyan Sheen, Yung-Chang Lin, Yung-Chang Lin
Innate-like bystander-activated CD38 + HLA-DR + CD8 + T cells play a pathogenic role in patients with chronic hepatitis C. Hepatology (Baltimore, Md.) 76 (3) (2022)
Yen-Chun Liu, Ya-Ting Cheng, Yi-Cheng Chen, Yi-Chung Hsieh, Wen-Juei Jeng, Chun-Yen Lin, Rong-Nan Chien, Dar-In Tai, I-Shyan Sheen
Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients. Digestive diseases and sciences (2022)
Wen-Juei Jeng, Mei-Hung Pan, Hwai-I Yang
Letter: sPD-1 as a predictor for HBsAg seroclearance-shed light on inactive carriers with chronic hepatitis B. Authors' reply. Alimentary pharmacology & therapeutics 55 (8) (2022)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies. Liver international : official journal of the International Association for the Study of the Liver 42 (3) (2022)
Wei Teng, Wen-Juei Jeng, Wei-Ting Chen, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen
Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients. Cancer medicine 11 (20) (2022)
Tzu-Ning Tseng, Wen-Juei Jeng, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Chien-Hung Chen
Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. The Journal of antimicrobial chemotherapy (2022)
Man Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, Wen-Juei Jeng, Magdy Elkhashab, Carla S Coffin, Won Kim, Susan Greenbloom, Alnoor Ramji, Young Suk Lim, Yoon Jun Kim, Scott K Fung, Dong Joon Kim, Jeong Won Jang, Kwan Sik Lee, Radhakrishnan P Iyer, Chelsea Macfarlane, Kathy Jackson, Stephen A Locarnini, Henry Lik Yuen Chan, Nezam H Afdhal
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B. Liver international : official journal of the International Association for the Study of the Liver (2022)
Chien-Wei Peng, Wen-Juei Jeng, Hwai-I Yang, Yen-Chun Liu, Rong-Nan Chien, Yun-Fan Liaw
A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study. Journal of gastroenterology and hepatology 37 (11) (2022)
Yen-Chun Liu, Wen-Juei Jeng
Editorial: is functional cure the only holy grail for treatment discontinuation in patients with HBeAg-negative chronic hepatitis B? Alimentary pharmacology & therapeutics 56 (3) (2022)
Amare Aregay, Bastian Engel, Kerstin Port, Florian W R Vondran, Birgit Bremer, Christian Niehaus, Tanvi Khera, Nicolas Richter, Elmar Jaeckel, Wen-Juei Jeng, Richard Taubert, Heiner Wedemeyer
Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 27 (6) (2021)
Wei Teng, Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Su
Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers 13 (7) (2021)
Chien-Wei Peng, Wen-Juei Jeng
The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients. Hepatology international 15 (2) (2021)
Wen-Juei Jeng, Yen-Chun Liu, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment. The Journal of antimicrobial chemotherapy (2021)
Freya Wellhöner, Nico Döscher, Franziska Woelfl, Marius Vital, Iris Plumeier, Silke Kahl, Andrej Potthoff, Michael Peter Manns, Dietmar Helmut Pieper, Wen-Juei Jeng, Heiner Wedemeyer, Benjamin Heidrich
Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology (Baltimore, Md.) 74 (1) (2021)
Wen-Juei Jeng, Yao-Chun Hsu, Tung-Hung Su, Chien-Hung Chen
Letter to the Editor: Deliberations More Than a Cut-off Hepatitis B Surface Antigen Value for Nucleos(t)ide Analogue Cessation. Hepatology (Baltimore, Md.) 70 (4) (2020)
Chien-Wei Peng, Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B. Journal of viral hepatitis 28 (3) (2020)
Maximilian Wübbolding, Juan Carlos Lopez Alfonso, Yung-Chang Lin, Sebastian Binder, Christine Falk, Jennifer Debarry, Paul Gineste, Anke R M Kraft, Rong-Nan Chien, Benjamin Maasoumy, Heiner Wedemeyer, Wen-Juei Jeng, Michael Meyer Hermann, Markus Cornberg, Christoph Höner Zu Siederdissen
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. Hepatology communications 5 (1) (2020)
Yen-Chun Liu, Wen-Juei Jeng, Ya-Ting Cheng, Yi-Chung Hsieh, Wei Teng, Yi-Cheng Chen, Chun-Yen Lin, Rong-Nan Chien, I-Shyan Sheen
Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine 99 (37) (2020)
Wen-Juei Jeng, Ming-Ling Chang, Yun-Fan Liaw
Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients. Journal of viral hepatitis 26 (8) (2019)
Shen-Yung Wang, Chih-Li Chen, Yu-Chen Hu, Yi Chi, Yen-Hua Huang, Chien-Wei Su, Wen-Juei Jeng, Yuh-Jin Liang, Jaw-Ching Wu
High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. Cancers 11 (10) (2019)
Wen-Juei Jeng, Hwai-I Yang
Discrepant range of sPD-1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. Journal of viral hepatitis 26 (7) (2019)